FILANA THERAPEUTICS, INC.

FLNASEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1069530

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue, Net (Deprecated 2018-01-31)	—	—	—	—	—
Research and Development Expense	$89.4M	$68.0M	$24.8M	—	—
Operating Expenses	$106.0M	$80.0M	$32.9M	$6.4M	$6.4M
Operating Income (Loss)	-$106.0M	-$80.0M	-$32.9M	-$6.4M	-$6.4M
Other Nonoperating Income (Expense)	$907.0K	$997.0K	$434.0K	$434.0K	$434.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	—	—	—
Income Tax Expense (Benefit)	$0.00	$0.00	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$157.5M	$151.7M	$234.8M	$266.8M	$94.3M
Assets, Current	$136.5M	$129.6M	$211.2M	$244.5M	$94.0M
Cash and Cash Equivalents, at Carrying Value	$128.6M	$121.1M	$201.0M	$233.4M	$93.5M
Liabilities	$11.8M	$14.2M	$7.3M	$12.9M	$2.1M
Liabilities, Current	$11.8M	$14.2M	$7.1M	$12.5M	$1.9M
Accounts Payable, Current	—	—	—	$7.1M	$911.0K
Stockholders' Equity Attributable to Parent	$227.5M	$253.9M	$92.2M	$22.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$82.0M	-$77.5M	-$30.2M	-$5.4M	-$5.4M
Net Cash Provided by (Used in) Investing Activities	-$414.0K	-$2.7M	-$22.2M	$360.0K	$360.0K
Net Cash Provided by (Used in) Financing Activities	$2.6M	$47.8M	$192.3M	$75.4M	$75.4M
Payments to Acquire Property, Plant, and Equipment	$414.0K	$2.7M	$22.2M	$22.2M	$22.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)